A Phase 2 interventional study of Ibuprofen/acetaminophen and Ibuprofen/acetaminophen in Pain, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-05-19.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 6th largest by enrollment, is one of 10 that started in 2012, is one of 8 in phase 2, and was the 28th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 10 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
74 studies in Pain by Pfizer: none open now, none under way, none of them phase 3. Of 72 finished, 34 (47%) have results posted.
Among the 74 studies in Pain by Pfizer, this one is the 19th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2012, is one of 20 in phase 2, and was the 57th registered.
Pfizer’s Pain studies by the year they started, since 2001.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 74 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will determine the overall analgesic efficacy of three different fixed dose ibuprofen plus acetaminophen formulations compared to ibuprofen alone and to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ibuprofen/acetaminophen
Drug: Ibuprofen/acetaminophen
Drug: Ibuprofen/acetaminophen
Drug: Ibuprofen
Drug: Placebo
Drug pages: Ibuprofen · Acetaminophen
Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
Drug pages: Ibuprofen · Acetaminophen
Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
Drug pages: Ibuprofen · Acetaminophen
Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
Two caplets of ibuprofen 200 mg
Two caplets of placebo
Time-Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 8 Hours (SPRID 0-8)
SPRID4:Time-weighted sum of pain relief rating (PRR) and pain intensity difference (PID) based on 4 point categorical severity rating scale (PRID) over 8 hours.SPRID 0-8 score range:-8 (worst score) to 56 (best score).PRID: sum of PRR and PID at each time point.PRID score range:-1= worst score to 7= best score.PID4 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[none\] to 3 \[severe\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -1 (worst score) to 3 (best score).PRR assessed on 5-point categorical scale with range:0 =no relief to 4 =complete relief.
Time frame: From 0 hour up to 8 hours post-dose
Time to Onset of Meaningful Pain Relief
Participants evaluated time to meaningful relief by stopping a second stopwatch labelled as "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
Time frame: From 0 hour up to 12 hours post-dose
Time to Confirmed First Perceptible Relief
Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labelled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure (defined as participant taking rescue medication, or discontinuing due to lack of efficacy) prior to depressing the first stopwatch or until the time of withdrawal (discontinuation).
Time frame: From 0 hour up to 12 hours post-dose
Pain Relief Rating Score (PRR)
Participants answered a question: "how much relief do you have from your starting pain? on a 5-point categorical pain relief rating scale. Scale ranges from 0= no relief to 4= complete relief.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Pain Intensity Difference on 4-Point Categorical Scale (PID4)
PID4: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on a 4-point categorical pain severity rating scale. PID4 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Pain Intensity Difference on 11-Point Numerical Scale (PID11)
PID11: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on an 11-point numerical pain severity rating scale. PID11 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID11: -5 (worst score) to 10 (best score).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (PRID4)
PRID4: sum of PID and PRR at each post-dose time points up to 12 hours. Score range for PRID: -1(worst score) to 7(best score). PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score). PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Time-weighted Sum of Pain Intensity Difference on 4-Point Categorical Scale (SPID4) Over 2, 6, 8 and 12 Hours Post-Dose
Pain intensity was assessed on a 4-point categorical pain severity rating scale. SPID4: Time-weighted sum of PID over post-dose time points. SPID4 score range was -2 (worst score) to 6 (best score) for SPID 0-2, -6 (worst score) to 18 (best score) for SPID 0-6, -8 (worst score) to 24 (best score) for SPID 0-8, -12 (worst score) to 36 (best score) for SPID 0-12. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[none\] to 3 \[severe\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -1 (worst score) to 3 (best score).
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12 hours post-dose
Time-weighted Sum of Pain Intensity Difference on 11-Point Numerical Scale (SPID11) Over 2, 6, 8 and 12 Hours Post-Dose
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11: Time-weighted sum of PID scores over 12 hours. SPID11 score range was -10 (worst score) to 20 (best score) for SPID 0-2, -30 (worst score) to 60 (best score) for SPID 0-6, -40 (worst score) to 80 (best score) for SPID 0-8, -60 (worst score) to 120 (best score) for SPID 0-12. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12 hours post-dose
Time-weighted Sum of Pain Relief Rating (TOTPAR) Over 2, 6, 8, 12 Hours Post-Dose
TOTPAR: time-weighted sum of PRR scores over 2, 6, 8 and 12 hours. TOTPAR score range was 0 (worst score) to 8 (best score) for TOTPAR 0-2, 0 (worst score) to 24 (best score) for TOTPAR 0-6, 0 (worst score) to 32 (best score) for TOTPAR 0-8, 0 (worst score) to 48 (best score) for TOTPAR 0-12. PRR was assessed on a 5-point categorical pain relief rating scale where 0= No relief to 4= Complete relief.
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 8 hours, 0 to 12 hours post-dose
Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference on 4-Point Categorical Scale (SPRID4) Over 2, 6 and 12 Hours Post Dose
SPRID4: Time-weighted sum of PRR and PID based on 4 point categorical pain severity rating scale (PRID) with score range: -2(worst score) to 14 (best score) for SPRID 0-2, -6 (worst score) to 42 (best score) for SPRID 0-6 and -12 (worst score) to 84 (best score) for SPRID 0-12. PRID: sum of PID and PRR at post-dose time point with score range: -1 (worst score) to 7 (best score). PID calculated by subtracting pain intensity score at post-dose time points (score range: 0 \[none\] to 3 \[severe\]) from baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline score of at least moderate were included). PID total possible score range: -1 (worst score) to 3(best score). PRR assessed on 5-point categorical scale with range: 0 =no relief to 4 =complete relief.
Time frame: 0 to 2 hours, 0 to 6 hours, 0 to 12 hours post-dose
Cumulative Percentage of Participants With Meaningful Relief
Percentage of participants with meaningful relief was reported. Participants evaluated time to meaningful relief by stopping a second stopwatch labeled "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Cumulative Percentage of Participants With Confirmed First Perceptible Relief
Percentage of participants with confirmed first perceptible relief was reported. Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labelled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure prior to depressing the first stopwatch or until the time of withdrawal (discontinuation). Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Time to Treatment Failure
Time to treatment failure was defined as the time interval from the study drug administration up to the first documentation of treatment failure. Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first.
Time frame: From 0 hour up to 12 hours post-dose
Cumulative Percentage of Participants With Treatment Failure
Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first. Percentage of participants who had treatment failure were reported.
Time frame: 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose
Participant Global Evaluation of Study Medication
Participant global evaluation of study medication was performed at the 12-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0= Very poor, 1= Poor, 2= Fair, 3= Good, 4= Very Good and 5= Excellent.
Time frame: 12 hour
| Milestone | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| Started | 30 | 90 | 93 | 89 | 92 |
| Completed | 30 | 89 | 92 | 88 | 92 |
| Not completed | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 |
SPRID4:Time-weighted sum of pain relief rating (PRR) and pain intensity difference (PID) based on 4 point categorical severity rating scale (PRID) over 8 hours.SPRID 0-8 score range:-8 (worst score) to 56 (best score).PRID: sum of PRR and PID at each time point.PRID score range:-1= worst score to 7= best score.PID4 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[none\] to 3 \[severe\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -1 (worst score) to 3 (best score).PRR assessed on 5-point categorical scale with range:0 =no relief to 4 =complete relief.
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| Time-Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 8 Hours (SPRID 0-8) | 5.0 ± 13.2 | 30.8 ± 12.7 | 29.6 ± 15.6 | 31.7 ± 14.6 | 28.8 ± 15.3 |
Participants evaluated time to meaningful relief by stopping a second stopwatch labelled as "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
| minutes | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| Time to Onset of Meaningful Pain Relief | NA (NA to NA) | 44.5 (37.0 to 55.0) | 54.1 (44.7 to 73.6) | 45.9 (42.2 to 57.2) | 56.2 (52.0 to 77.0) |
Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labelled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure (defined as participant taking rescue medication, or discontinuing due to lack of efficacy) prior to depressing the first stopwatch or until the time of withdrawal (discontinuation).
| minutes | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| Time to Confirmed First Perceptible Relief | NA (NA to NA) | 18.5 (15.7 to 23.0) | 22.8 (19.9 to 27.4) | 18.5 (15.7 to 21.8) | 24.9 (21.6 to 28.7) |
Participants answered a question: "how much relief do you have from your starting pain? on a 5-point categorical pain relief rating scale. Scale ranges from 0= no relief to 4= complete relief.
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0.25 hour | 0.2 ± 0.4 | 0.6 ± 0.8 | 0.5 ± 0.8 | 0.7 ± 0.9 | 0.4 ± 0.6 |
| 0.5 hour | 0.3 ± 0.5 | 1.7 ± 1.0 | 1.5 ± 1.2 | 1.6 ± 1.1 | 1.1 ± 0.9 |
| 1 hour | 0.4 ± 0.6 | 2.5 ± 1.1 | 2.3 ± 1.1 | 2.5 ± 1.2 | 2.1 ± 1.1 |
| 1.5 hour | 0.4 ± 0.8 | 2.8 ± 0.9 | 2.6 ± 1.1 | 2.8 ± 1.0 | 2.5 ± 1.2 |
| 2 hour | 0.4 ± 0.8 | 2.9 ± 1.0 | 2.7 ± 1.2 | 2.9 ± 1.1 | 2.6 ± 1.3 |
| 3 hour | 0.5 ± 1.0 | 2.9 ± 1.0 | 2.8 ± 1.2 | 3.0 ± 1.2 | 2.7 ± 1.3 |
| 4 hour | 0.5 ± 1.1 | 2.9 ± 1.0 | 2.7 ± 1.3 | 2.9 ± 1.2 | 2.7 ± 1.4 |
| 5 hour | 0.5 ± 1.1 | 2.7 ± 1.1 | 2.6 ± 1.3 | 2.8 ± 1.3 | 2.6 ± 1.4 |
| 6 hour | 0.6 ± 1.2 | 2.5 ± 1.3 | 2.4 ± 1.4 | 2.7 ± 1.4 | 2.4 ± 1.5 |
| 7 hour | 0.6 ± 1.2 | 2.1 ± 1.4 | 2.2 ± 1.4 | 2.3 ± 1.4 | 2.1 ± 1.5 |
| 8 hour | 0.6 ± 1.2 | 1.7 ± 1.5 | 1.9 ± 1.4 | 1.9 ± 1.5 | 1.9 ± 1.5 |
| 9 hour | 0.6 ± 1.2 | 1.4 ± 1.5 | 1.5 ± 1.4 | 1.7 ± 1.5 | 1.7 ± 1.5 |
| 10 hour | 0.6 ± 1.2 | 1.2 ± 1.4 | 1.2 ± 1.3 | 1.5 ± 1.5 | 1.4 ± 1.5 |
| 11 hour | 0.6 ± 1.3 | 0.9 ± 1.4 | 1.0 ± 1.3 | 1.3 ± 1.4 | 1.3 ± 1.5 |
| 12 hour | 0.6 ± 1.3 | 0.8 ± 1.3 | 0.9 ± 1.2 | 1.1 ± 1.3 | 1.2 ± 1.4 |
PID4: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on a 4-point categorical pain severity rating scale. PID4 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score).
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0.25 hour | 0.1 ± 0.3 | 0.3 ± 0.6 | 0.2 ± 0.4 | 0.3 ± 0.6 | 0.2 ± 0.4 |
| 0.5 hour | 0.1 ± 0.4 | 0.9 ± 0.8 | 0.7 ± 0.8 | 0.8 ± 0.8 | 0.5 ± 0.7 |
| 1 hour | 0.1 ± 0.6 | 1.5 ± 0.9 | 1.2 ± 0.8 | 1.4 ± 0.9 | 1.1 ± 0.9 |
| 1.5 hour | 0.1 ± 0.7 | 1.6 ± 0.8 | 1.5 ± 1.0 | 1.6 ± 0.9 | 1.4 ± 0.9 |
| 2 hour | 0.0 ± 0.7 | 1.7 ± 0.9 | 1.6 ± 1.0 | 1.7 ± 0.9 | 1.5 ± 0.9 |
| 3 hour | 0.1 ± 0.8 | 1.7 ± 0.9 | 1.6 ± 1.0 | 1.7 ± 1.0 | 1.6 ± 1.0 |
| 4 hour | 0.1 ± 0.9 | 1.7 ± 0.9 | 1.6 ± 1.1 | 1.7 ± 0.9 | 1.6 ± 1.0 |
| 5 hour | 0.1 ± 0.9 | 1.6 ± 0.9 | 1.5 ± 1.1 | 1.6 ± 1.0 | 1.5 ± 1.0 |
| 6 hour | 0.2 ± 0.9 | 1.4 ± 1.0 | 1.4 ± 1.1 | 1.6 ± 1.1 | 1.3 ± 1.0 |
| 7 hour | 0.2 ± 0.9 | 1.2 ± 1.0 | 1.2 ± 1.1 | 1.3 ± 1.1 | 1.2 ± 1.0 |
| 8 hour | 0.2 ± 0.9 | 0.9 ± 1.0 | 1.0 ± 1.0 | 1.0 ± 1.0 | 1.0 ± 1.1 |
| 9 hour | 0.2 ± 0.9 | 0.8 ± 1.0 | 0.7 ± 1.0 | 0.8 ± 0.9 | 0.8 ± 1.0 |
| 10 hour | 0.2 ± 1.0 | 0.6 ± 0.9 | 0.6 ± 0.9 | 0.7 ± 0.9 | 0.7 ± 1.0 |
| 11 hour | 0.2 ± 1.0 | 0.5 ± 1.0 | 0.5 ± 0.9 | 0.6 ± 0.9 | 0.6 ± 0.9 |
| 12 hour | 0.3 ± 1.1 | 0.3 ± 0.8 | 0.4 ± 0.8 | 0.4 ± 0.8 | 0.5 ± 0.8 |
PID11: baseline pain severity score minus pain severity score at a given time point. Pain intensity was assessed on an 11-point numerical pain severity rating scale. PID11 was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID11: -5 (worst score) to 10 (best score).
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0.25 hour | 0.1 ± 0.6 | 1.0 ± 1.6 | 0.8 ± 1.3 | 0.9 ± 1.6 | 0.4 ± 1.0 |
| 0.5 hour | 0.2 ± 1.1 | 3.0 ± 2.3 | 2.5 ± 2.3 | 2.6 ± 2.3 | 1.7 ± 1.8 |
| 1 hour | 0.1 ± 1.4 | 4.7 ± 2.5 | 4.2 ± 2.6 | 4.5 ± 2.4 | 3.8 ± 2.6 |
| 1.5 hour | 0.0 ± 1.7 | 5.3 ± 2.4 | 5.0 ± 2.8 | 5.3 ± 2.4 | 4.6 ± 2.7 |
| 2 hour | -0.1 ± 1.8 | 5.5 ± 2.5 | 5.3 ± 3.0 | 5.6 ± 2.5 | 5.0 ± 2.8 |
| 3 hour | 0.1 ± 2.2 | 5.7 ± 2.5 | 5.5 ± 3.0 | 5.7 ± 2.7 | 5.2 ± 2.9 |
| 4 hour | 0.3 ± 2.5 | 5.5 ± 2.5 | 5.4 ± 3.1 | 5.6 ± 2.7 | 5.1 ± 3.0 |
| 5 hour | 0.2 ± 2.4 | 5.3 ± 2.6 | 5.1 ± 3.2 | 5.3 ± 3.0 | 4.9 ± 3.0 |
| 6 hour | 0.4 ± 2.6 | 4.6 ± 2.9 | 4.8 ± 3.3 | 5.0 ± 3.1 | 4.4 ± 3.2 |
| 7 hour | 0.3 ± 2.5 | 3.9 ± 2.9 | 4.2 ± 3.2 | 4.2 ± 3.1 | 3.9 ± 3.2 |
| 8 hour | 0.3 ± 2.6 | 3.1 ± 3.0 | 3.5 ± 3.2 | 3.2 ± 3.0 | 3.5 ± 3.2 |
| 9 hour | 0.5 ± 2.8 | 2.5 ± 3.0 | 2.7 ± 3.1 | 2.8 ± 3.0 | 2.9 ± 3.0 |
| 10 hour | 0.6 ± 3.0 | 1.9 ± 2.8 | 2.1 ± 3.0 | 2.5 ± 2.9 | 2.5 ± 3.0 |
| 11 hour | 0.6 ± 2.9 | 1.6 ± 2.8 | 1.7 ± 2.9 | 2.0 ± 2.6 | 2.2 ± 2.9 |
| 12 hour | 0.7 ± 3.2 | 1.1 ± 2.4 | 1.5 ± 2.6 | 1.7 ± 2.5 | 1.9 ± 2.6 |
PRID4: sum of PID and PRR at each post-dose time points up to 12 hours. Score range for PRID: -1(worst score) to 7(best score). PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[no pain\] to 3 \[worst possible pain\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID4: -1 (worst score) to 3 (best score). PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0.25 hour | 0.3 ± 0.6 | 1.0 ± 1.3 | 0.7 ± 1.1 | 1.0 ± 1.4 | 0.6 ± 1.0 |
| 0.5 hour | 0.3 ± 0.9 | 2.6 ± 1.8 | 2.2 ± 1.9 | 2.4 ± 1.8 | 1.6 ± 1.4 |
| 1 hour | 0.5 ± 1.1 | 4.0 ± 1.8 | 3.6 ± 1.8 | 3.9 ± 1.9 | 3.2 ± 1.9 |
| 1.5 hour | 0.5 ± 1.4 | 4.5 ± 1.7 | 4.1 ± 2.0 | 4.5 ± 1.8 | 3.9 ± 1.9 |
| 2 hour | 0.4 ± 1.4 | 4.6 ± 1.8 | 4.3 ± 2.1 | 4.7 ± 1.9 | 4.2 ± 2.1 |
| 3 hour | 0.6 ± 1.8 | 4.6 ± 1.8 | 4.4 ± 2.2 | 4.7 ± 2.0 | 4.3 ± 2.2 |
| 4 hour | 0.7 ± 1.9 | 4.5 ± 1.8 | 4.3 ± 2.3 | 4.6 ± 2.0 | 4.2 ± 2.3 |
| 5 hour | 0.6 ± 1.9 | 4.3 ± 1.9 | 4.1 ± 2.4 | 4.4 ± 2.3 | 4.1 ± 2.3 |
| 6 hour | 0.8 ± 2.0 | 3.8 ± 2.2 | 3.9 ± 2.4 | 4.2 ± 2.4 | 3.7 ± 2.5 |
| 7 hour | 0.7 ± 2.0 | 3.3 ± 2.3 | 3.4 ± 2.4 | 3.6 ± 2.4 | 3.3 ± 2.5 |
| 8 hour | 0.7 ± 2.0 | 2.7 ± 2.4 | 2.9 ± 2.3 | 2.8 ± 2.4 | 3.0 ± 2.5 |
| 9 hour | 0.8 ± 2.0 | 2.2 ± 2.4 | 2.2 ± 2.3 | 2.5 ± 2.3 | 2.5 ± 2.4 |
| 10 hour | 0.8 ± 2.2 | 1.7 ± 2.3 | 1.7 ± 2.2 | 2.2 ± 2.3 | 2.1 ± 2.4 |
| 11 hour | 0.9 ± 2.3 | 1.4 ± 2.3 | 1.5 ± 2.2 | 1.9 ± 2.2 | 1.9 ± 2.4 |
| 12 hour | 0.9 ± 2.4 | 1.1 ± 2.0 | 1.2 ± 2.0 | 1.6 ± 2.1 | 1.7 ± 2.2 |
Pain intensity was assessed on a 4-point categorical pain severity rating scale. SPID4: Time-weighted sum of PID over post-dose time points. SPID4 score range was -2 (worst score) to 6 (best score) for SPID 0-2, -6 (worst score) to 18 (best score) for SPID 0-6, -8 (worst score) to 24 (best score) for SPID 0-8, -12 (worst score) to 36 (best score) for SPID 0-12. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 \[none\] to 3 \[severe\]) from the baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -1 (worst score) to 3 (best score).
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0 to 2 hours | 0.1 ± 1.0 | 2.7 ± 1.5 | 2.4 ± 1.5 | 2.7 ± 1.4 | 2.2 ± 1.4 |
| 0 to 6 hours | 0.7 ± 4.4 | 9.1 ± 4.5 | 8.5 ± 5.4 | 9.3 ± 5.0 | 8.2 ± 4.9 |
| 0 to 8 hours | 1.0 ± 6.1 | 11.2 ± 6.1 | 10.7 ± 7.2 | 11.6 ± 6.6 | 10.4 ± 6.7 |
| 0 to 12 hours | 2.0 ± 10.0 | 13.3 ± 8.8 | 12.9 ± 9.9 | 14.1 ± 9.1 | 13.0 ± 9.4 |
Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11: Time-weighted sum of PID scores over 12 hours. SPID11 score range was -10 (worst score) to 20 (best score) for SPID 0-2, -30 (worst score) to 60 (best score) for SPID 0-6, -40 (worst score) to 80 (best score) for SPID 0-8, -60 (worst score) to 120 (best score) for SPID 0-12. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0 to 2 hours | 0.1 ± 2.4 | 8.8 ± 4.3 | 8.0 ± 4.5 | 8.6 ± 4.0 | 7.2 ± 4.3 |
| 0 to 6 hours | 1.1 ± 11.8 | 29.9 ± 13.0 | 28.8 ± 16.1 | 30.1 ± 14.4 | 26.8 ± 15.0 |
| 0 to 8 hours | 1.8 ± 16.8 | 36.9 ± 17.3 | 36.5 ± 21.5 | 37.6 ± 19.3 | 34.2 ± 20.3 |
| 0 to12 hours | 4.1 ± 28.7 | 44.0 ± 25.0 | 44.5 ± 29.7 | 46.5 ± 27.3 | 43.7 ± 29.2 |
TOTPAR: time-weighted sum of PRR scores over 2, 6, 8 and 12 hours. TOTPAR score range was 0 (worst score) to 8 (best score) for TOTPAR 0-2, 0 (worst score) to 24 (best score) for TOTPAR 0-6, 0 (worst score) to 32 (best score) for TOTPAR 0-8, 0 (worst score) to 48 (best score) for TOTPAR 0-12. PRR was assessed on a 5-point categorical pain relief rating scale where 0= No relief to 4= Complete relief.
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0 to 2 hours | 0.7 ± 1.1 | 4.7 ± 1.7 | 4.3 ± 1.9 | 4.7 ± 1.8 | 4.0 ± 1.8 |
| 0 to 6 hours | 2.8 ± 5.4 | 15.7 ± 5.2 | 14.8 ± 6.5 | 16.0 ± 6.3 | 14.3 ± 6.7 |
| 0 to 8 hours | 4.0 ± 7.6 | 19.6 ± 7.2 | 18.9 ± 8.8 | 20.2 ± 8.6 | 18.4 ± 9.2 |
| 0 to 12 hours | 6.4 ± 12.6 | 23.9 ± 11.2 | 23.4 ± 12.6 | 25.8 ± 12.9 | 23.9 ± 13.8 |
SPRID4: Time-weighted sum of PRR and PID based on 4 point categorical pain severity rating scale (PRID) with score range: -2(worst score) to 14 (best score) for SPRID 0-2, -6 (worst score) to 42 (best score) for SPRID 0-6 and -12 (worst score) to 84 (best score) for SPRID 0-12. PRID: sum of PID and PRR at post-dose time point with score range: -1 (worst score) to 7 (best score). PID calculated by subtracting pain intensity score at post-dose time points (score range: 0 \[none\] to 3 \[severe\]) from baseline pain intensity scores (score range: 2 =moderate pain to 3 = severe pain; as participants with baseline score of at least moderate were included). PID total possible score range: -1 (worst score) to 3(best score). PRR assessed on 5-point categorical scale with range: 0 =no relief to 4 =complete relief.
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0 to 2 hours | 0.9 ± 2.0 | 7.4 ± 3.0 | 6.7 ± 3.2 | 7.4 ± 3.1 | 6.2 ± 3.1 |
| 0 to 6 hours | 3.5 ± 9.4 | 24.8 ± 9.2 | 23.3 ± 11.6 | 25.3 ± 10.9 | 22.5 ± 11.2 |
| 0 to 12 hours | 8.4 ± 22.0 | 37.2 ± 19.2 | 36.3 ± 21.9 | 39.9 ± 21.1 | 36.9 ± 22.4 |
Percentage of participants with meaningful relief was reported. Participants evaluated time to meaningful relief by stopping a second stopwatch labeled "meaningful relief" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
| percentage of participants | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0.25 hours | 0.0 | 1.1 | 1.1 | 3.4 | 1.1 |
| 0.5 hours | 0.0 | 33.3 | 23.7 | 22.5 | 13.0 |
| 1 hour | 3.3 | 65.6 | 54.8 | 67.4 | 54.3 |
| 1.5 hours | 6.7 | 81.1 | 69.9 | 77.5 | 66.3 |
| 2 hours | 10.0 | 85.6 | 77.4 | 84.3 | 73.9 |
| 3 hours | 10.0 | 90.0 | 81.7 | 88.8 | 80.4 |
| 4 hours | 13.3 | 90.0 | 83.9 | 89.9 | 81.5 |
| 5 hours | 13.3 | 91.1 | 84.9 | 89.9 | 82.6 |
| 6 hours | 16.7 | 91.1 | 86.0 | 89.9 | 83.7 |
| 7 hours | 16.7 | 91.1 | 87.1 | 89.9 | 84.8 |
| 8 hours | 16.7 | 91.1 | 88.2 | 89.9 | 85.9 |
| 9 hours | 16.7 | 91.1 | 88.2 | 89.9 | 85.9 |
| 10 hours | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 11 hours | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 12 hours | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
Percentage of participants with confirmed first perceptible relief was reported. Participants evaluated the time to first perceptible relief (confirmed by meaningful relief) by stopping the first stopwatch labelled 'first perceptible relief' at the moment they first began to experience any pain relief, if the participant also achieved meaningful relief by the end of the study. Stopwatch was active up to 12 hours after dosing or until stopped by the participant, or until the participant dropped out due to treatment failure prior to depressing the first stopwatch or until the time of withdrawal (discontinuation). Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.
| percentage of participants | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 0.25 hour | 3.3 | 26.7 | 18.3 | 28.1 | 19.6 |
| 0.5 hour | 10.0 | 73.3 | 66.7 | 77.5 | 63.0 |
| 1 hour | 16.7 | 88.9 | 83.9 | 88.8 | 80.4 |
| 1.5 hour | 16.7 | 91.1 | 86.0 | 89.9 | 84.8 |
| 2 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 3 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 4 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 5 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 6 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 7 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 8 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 9 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 10 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 11 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
| 12 hour | 20.0 | 91.1 | 88.2 | 89.9 | 85.9 |
Time to treatment failure was defined as the time interval from the study drug administration up to the first documentation of treatment failure. Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first.
| hours | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| Time to Treatment Failure | 1.6 (1.3 to 1.8) | 9.7 (8.7 to NA) | 10.1 (9.2 to 12) | 11.1 (9.2 to NA) | 10.4 (9.2 to NA) |
Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first. Percentage of participants who had treatment failure were reported.
| percentage of participants | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| 1.5 hour | 43.3 | 2.2 | 2.2 | 4.5 | 5.4 |
| 2 hour | 73.3 | 2.2 | 6.5 | 5.6 | 10.9 |
| 3 hour | 80.0 | 2.2 | 8.6 | 6.7 | 13.0 |
| 4 hour | 80.0 | 3.3 | 9.7 | 7.9 | 15.2 |
| 5 hour | 80.0 | 4.4 | 14.0 | 10.1 | 15.2 |
| 6 hour | 80.0 | 8.9 | 18.3 | 14.6 | 20.7 |
| 7 hour | 80.0 | 17.8 | 20.4 | 15.7 | 27.2 |
| 8 hour | 80.0 | 28.9 | 23.7 | 25.8 | 32.6 |
| 9 hour | 80.0 | 40.0 | 33.3 | 36.0 | 35.9 |
| 10 hour | 80.0 | 51.1 | 46.2 | 42.7 | 45.7 |
| 11 hour | 80.0 | 57.8 | 53.8 | 48.3 | 53.3 |
| 12 hour | 80.0 | 64.4 | 57.0 | 50.6 | 55.4 |
Participant global evaluation of study medication was performed at the 12-hour time point or immediately before taking the rescue medication. It was scored on a 6-point categorical scale where 0= Very poor, 1= Poor, 2= Fair, 3= Good, 4= Very Good and 5= Excellent.
| units on a scale | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| Participant Global Evaluation of Study Medication | 1.0 ± 1.5 | 3.8 ± 1.1 | 3.4 ± 1.2 | 3.6 ± 1.2 | 3.5 ± 1.4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/30 (0%) | 15/30 (50%) |
| Ibuprofen 200 mg + Acetaminophen 500 mg | — | 0/90 (0%) | 33/90 (36.7%) |
| Ibuprofen 250 mg + Acetaminophen 500 mg | — | 0/93 (0%) | 27/93 (29%) |
| Ibuprofen 300 mg + Acetaminophen 500 mg | — | 0/89 (0%) | 22/89 (24.7%) |
| Ibuprofen 400 mg | — | 0/92 (0%) | 30/92 (32.6%) |
| Event | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 14/30 | 22/90 | 18/93 | 16/89 | 22/92 |
| VomitingGastrointestinal disorders | 7/30 | 8/90 | 11/93 | 5/89 | 14/92 |
| DizzinessCardiac disorders | 3/30 | 9/90 | 6/93 | 7/89 | 7/92 |
| Feeling hotGeneral disorders | 2/30 | 4/90 | 1/93 | 4/89 | 4/92 |
| Alveolar osteitisGastrointestinal disorders | 0/30 | 4/90 | 2/93 | 1/89 | 2/92 |
| Tension headacheNervous system disorders | 0/30 | 4/90 | 1/93 | 1/89 | 4/92 |
| TremorNervous system disorders | 1/30 | 1/90 | 2/93 | 3/89 | 2/92 |
| Post procedural haemorrhageVascular disorders | 0/30 | 0/90 | 2/93 | 3/89 | 0/92 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/30 | 0/90 | 0/93 | 0/89 | 0/92 |
| ParaesthesiaNervous system disorders | 1/30 | 0/90 | 0/93 | 0/89 | 0/92 |
Intent-to-treat (ITT) population included all randomized participants who received study medication and provided a baseline assessment.
| Age, Continuous(years) | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 18.3 ± 2.6 | 17.7 ± 1.8 | 18.4 ± 2.1 | 17.8 ± 1.8 | 18.4 ± 1.9 | 18.1 ± 2.0 |
| Sex: Female, Male(Participants) | Placebo | Ibuprofen 200 mg + Acetaminophen 500 mg | Ibuprofen 250 mg + Acetaminophen 500 mg | Ibuprofen 300 mg + Acetaminophen 500 mg | Ibuprofen 400 mg | Total |
|---|---|---|---|---|---|---|
| Female | 15 | 46 | 50 | 43 | 46 | 200 |
| Male | 15 | 44 | 43 | 46 | 46 | 194 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2012 to primary completion in Sep 2012, 5 months.
Results were first posted in May 2020, 7 years 8 months after primary completion. A results delay was requested in Jul 2014.
Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 5 months is below that.
Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuprofen · Acetaminophen